Farmax India Limited reported revised audited standalone earnings results for fourth quarter and year end and consolidated earnings results for the year ended March 31, 2015. For the quarter, the company's net income from operations was INR 79.760 million compared to INR 42.324 million a year ago. Profit from operations before other income, provision and exceptional items were INR 31.481 million compared to INR 5.020 million a year ago. Profit from ordinary activities before tax was INR 46.810 million compared to INR 5.949 million a year ago. Net profit was INR 46.810 million or INR 0.09 per basic and diluted share before and after extraordinary items compared to INR 5.951 million for the same period a year ago.

For the year, the company's net income from operations was INR 210.456 million compared to INR 174.054 million a year ago. Loss from operations before other income, provision and exceptional items were INR 38.853 million compared to INR 92.210 million a year ago. Loss from ordinary activities before tax was INR 21.011 million compared to INR 88.430 million a year ago. Net loss was INR 21.011 million or INR 0.04 per basic and diluted share before and after extraordinary items compared to INR 88.430 million or INR 0.22 per basic and diluted share before and after extraordinary items for the same period a year ago.

For the year, on consolidated basis, the company's net income from operations was INR 210.456 million compared to INR 174.054 million a year ago. Loss from operations before other income, provision and exceptional items were INR 39.276 million compared to INR 92.618 million a year ago. Loss from ordinary activities before tax was INR 21.434 million compared to INR 88.839 million a year ago. Net loss was INR 21.434 million or INR 4.03 per basic and diluted share before and after extraordinary items compared to INR 88.839 million or INR 4.03 per basic and diluted share before and after extraordinary items for the same period a year ago. The company announced that there has been a type error in the financial statement submitted for the quarter and year ended on March 31, 2015. The typographical error occurred in the statement of assets and liabilities of the result. Therefore the company is enclosing the revised result.